{"product_id":"glp-r-retatrutide-12-mg","title":"GLP-3 (Retatrutide) Injection 12 mg","description":"\u003cp\u003eGLP-R (Retatrutide) is a synthetic peptide compound supplied in lyophilized powder form and documented through batch-specific analytical characterization. This material is prepared through controlled manufacturing processes and is accompanied by supporting documentation describing molecular identity and analytical measurement.\u003c\/p\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003e\u003cstrong\u003eRetatrutide\u003c\/strong\u003e is an injectable peptide drug\u003c\/span\u003e. \u003c\/p\u003e\n\u003cp\u003eIt is a \u003cstrong\u003enovel triple agonist\u003c\/strong\u003e, meaning it targets and activates \u003cstrong\u003ethree different metabolic hormone receptors:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGLP-1 (Glucagon-Like Peptide-1)\u003c\/li\u003e\n\u003cli\u003eGIP (Glucose-Dependent Insulinotropic Polypeptide)\u003c\/li\u003e\n\u003cli\u003eGlucagon receptor\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eYou might see it called a \u003cstrong\u003e“triple hormone receptor agonist”\u003c\/strong\u003e or “triple incretin.”\u003c\/p\u003e\n\u003ch2\u003e\u003cstrong\u003eWhat is Retatrutide Used For?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003ch3\u003e\u003cstrong\u003eClinical Indications (Current and Investigational):\u003c\/strong\u003e\u003c\/h3\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eObesity \u0026amp; Weight Loss (Main Use):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIndicated for chronic weight management in people with overweight or obesity (with or without diabetes).\u003c\/li\u003e\n\u003cli\u003eIn Phase 2 trials, Retatrutide produced average \u003cstrong\u003eweight loss up to 24.2% of body weight at 48 weeks\u003c\/strong\u003e, with some patients losing over 25%—more than any other available medication to date.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eType 2 Diabetes:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eImproved blood sugar control due to its effects on insulin, glucagon, and appetite. Clinical trials are ongoing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003ePotential Future Uses (under study):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNonalcoholic fatty liver disease (NAFLD)\/NASH (due to fat reduction and metabolic benefits).\u003c\/li\u003e\n\u003cli\u003eGeneral cardiometabolic syndrome (cholesterol, blood pressure, etc.).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2\u003e\u003cstrong\u003eKey Findings in Clinical Trials\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eWeight Loss:\u003c\/strong\u003e Retatrutide produced the highest weight loss observed in clinical studies for any obesity drug—greater \u003cem\u003eon average\u003c\/em\u003e than tirzepatide (Zepbound\/Mounjaro) or semaglutide (Wegovy\/Ozempic).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBlood Sugar:\u003c\/strong\u003e Strong improvement in blood sugar levels in Type 2 diabetes patients.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSafety:\u003c\/strong\u003e Side effects are similar to those of other GLP-1 drugs—mainly gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation). Most are mild-moderate and lessen over time.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCardiovascular Outcomes:\u003c\/strong\u003e No evidence of increased adverse cardiovascular effects in short- to medium-term studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cstrong\u003eHow is Retatrutide Given?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eRoute:\u003c\/strong\u003e Subcutaneous (under-skin) injection\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFrequency:\u003c\/strong\u003e Once weekly\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDosing:\u003c\/strong\u003e Titrated upward over weeks to reduce side effects\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cstrong\u003eWho Should Consider Retatrutide?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdults with obesity\u003c\/strong\u003e (BMI ≥30) or \u003cstrong\u003eoverweight\u003c\/strong\u003e (BMI ≥27) with a weight-related co-morbidity\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePeople with Type 2 diabetes\u003c\/strong\u003e needing weight loss and improved glycemic control\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNot approved for:\u003c\/strong\u003e People with Type 1 diabetes; children (unless\/when pediatric studies are completed)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cstrong\u003eSide Effects \u0026amp; Risks\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eMost common (GI-related):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNausea\u003c\/li\u003e\n\u003cli\u003eVomiting\u003c\/li\u003e\n\u003cli\u003eDiarrhea\/constipation\u003c\/li\u003e\n\u003cli\u003eDecreased appetite\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOthers:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePossible risk of gallbladder problems, rare pancreatitis, temporary elevation of heart rate (similar to other incretin drugs)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eContraindications:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePersonal\/family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (based on GLP-1 class warning)\u003c\/li\u003e\n\u003cli\u003eHypersensitivity to ingredients\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003e\u003cstrong\u003eGLP-3 (Retatrutide) Injection\u003c\/strong\u003e is a ground-breaking, triple-action, weekly injectable drug for substantial weight loss and metabolic improvement. Its expected future use is for obesity, type 2 diabetes, and potentially related metabolic diseases, outperforming any currently available medication in clinical trials. \u003c\/span\u003e\u003c\/p\u003e","brand":"Mountainside Medical","offers":[{"title":"Default Title","offer_id":54255382397296,"sku":"Reta","price":150.0,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/Retatrutide-Weight-Loss-Injection.jpg?v=1788358324","url":"https:\/\/www.mountainside-medical.com\/products\/glp-r-retatrutide-12-mg","provider":"Mountainside Medical","version":"1.0","type":"link"}